Autres langues Olema Pharmaceuticals, Inc.

Actions

OLMA

US68062P1066

Temps réel estimé Cboe BZX Autres places de cotation 19:22:06 30/04/2024			Varia. 5j.	Varia. 1 janv.
10,18 ^USD	+0,15 %		+1,90 %	-27,37 %

02/04	OLEMA PHARMACEUTICALS, INC. : Goldman Sachs adopte une opinion positive	ZM
12/03	OLEMA PHARMACEUTICALS, INC. : HC Wainwright à l'achat	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference	08/04
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/04
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to S&P Biotechnology Select Industry Index	18/03
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	11/03
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update	11/03
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	11/03
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors	06/03
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors	06/03
Olema Oncology Announces Publication of Data Highlighting Palazestrant?s Ability to Inhibit Wild-Type and Mutant Er+ Breast Cancer Both as Monotherapy and in Combination with Cdk4/6 Inhibitors	06/03
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/03
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/03
Olema Oncology to Participate in Upcoming Investor Conferences	06/02
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/02
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/02
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate	08/01
Olema Pharmaceuticals, Inc. Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate	08/01
Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference	02/01
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to NASDAQ Biotechnology Index	18/12
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies	05/12
Olema Pharmaceuticals, Inc. Announces Palazestrant Demonstrates Attractive Combinability with Cdk4/6 Inhibitors Ribociclib and Palbociclib in Phase 1B/2 Studies	05/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Olema Pharmaceuticals, Inc.

Actions

OLMA

US68062P1066

Autres langues

Filtres